Xtant Medical Holdings Reports 18% Revenue Increase to $35.4M and $3.6M Net Income in Q2 2025
Reuters
Aug 12
Xtant Medical Holdings Reports 18% Revenue Increase to $35.4M and $3.6M Net Income in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025
Xtant Medical Holdings Inc. has reported strong financial results for the second quarter of 2025, with total revenue reaching $35.4 million, marking an 18% increase compared to the same quarter in 2024. This growth is primarily attributed to increased sales in orthobiologics and licensing revenue. The company reported a net income of $3.6 million, a significant turnaround from a net loss of $3.9 million in the prior year quarter. The gross margin also improved to 68.6% from 62.1% in the previous year quarter. Additionally, Xtant Medical has raised its full-year 2025 revenue guidance to a range of $131 million to $135 million, representing a growth of 11% to 15% over the company's 2024 revenue. This updated guidance surpasses the prior forecast of $127 million to $131 million. In recent business developments, Xtant Medical announced definitive agreements to sell its non-core Coflex® and CoFix® spinal implants and all OUS businesses to Companion Spine for approximately $19.2 million. This transaction aims to strengthen the company's balance sheet and support the development of its pipeline of advanced biologics.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtant Medical Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA48866) on August 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.